Fermenta Biotech Quarterly Results for Trading Insights
In Sept 2025, Fermenta Biotech (FERMENTA) reported revenue ₹136 Cr and net profit ₹18 Cr — revenue +38.8% YoY. Also explore FERMENTA share price history to track price trends across different timeframes.
FERMENTA Quarterly Results — Revenue, Profit & EPS Highlights
Fermenta Biotech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit FERMENTA screener.
- Revenue of ₹136 Cr in Sept 2025 (-5.6% vs Mar 2025, +38.8% vs Sept 2024)
- Net Profit of ₹18 Cr in Sept 2025 (-45.5% vs Mar 2025, +63.6% vs Sept 2024)
- EBITDA of ₹32 Cr in Sept 2025 (-22.0% vs Mar 2025)
- Operating Margin of 20.0% in Sept 2025 (-6.0pp vs Mar 2025)
- Earnings Per Share of ₹6.20 in Sept 2025 (-47.4% vs Mar 2025)
Fermenta Biotech Quarterly Results — Revenue, EBITDA, Net Profit & EPS
FERMENTA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 136 | 144 | 145 | 141 | 98 | -5.6% | 38.8% |
| Net Profit (₹ Cr) | 18 | 33 | 22 | 12 | 11 | - | - |
| EBITDA (₹ Cr) | 32 | 41 | 37 | 26 | 22 | - | - |
| EPS (₹) | 6.20 | 11.79 | 7.49 | 4.36 | 3.94 | - | - |
| Operating Margin (%) | 20.0% | 26.0% | 21.0% | 17.0% | 20.0% | - | - |
FERMENTA Share Price Trend — 1-Year Movement Across Quarterly Results
Fermenta Biotech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with FERMENTA fair value estimate to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
FERMENTA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Fermenta Biotech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1844.6 | 14,875 | 3,125 | +10.8% | - | 21.0% | 141.9 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6887.0 | 2,860 | 689 | +7.1% | - | 24.1% | 265.2 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4486.2 | 3,219 | 591 | +11.3% | - | 18.4% | 255.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1399.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 203.7 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1307.2 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 493.3 |
All amounts in ₹ Crores